Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Akie Hirata, Kaname Miyashita, Takafumi Tanaka, Kiyoko Hirata, Taisuke Narazaki, Hayato Utsunomiya, Hirofumi Ohno, Eriko Nakashima, Yoshimichi Tachikawa, Ilseung Choi, Kenichi Taguchi & Youko Suehiro. (2022) Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab. Hematology 27:1, pages 384-395.
Read now
Read now
Paolo Strati, Mohamed Amin Ahmed, Loretta J. Nastoupil, Lei Feng, Fredrick B. Hagemeister, Luis E. Fayad, Maria A. Rodriguez, Felipe Samaniego, Michael Wang, Jason R. Westin, Hun J. Lee, Swaminathan P. Iyer, Simrit Parmar, Sairah Ahmed, Ranjit Nair, Raphael E. Steiner, Mansoor Noorani, Christopher R. Flowers, R. Eric Davis, Nathan H. Fowler & Sattva S. Neelapu. (2020) Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia & Lymphoma 61:6, pages 1380-1387.
Read now
Read now
Antonio Rueda, Virginia Calvo, María Casanova, Delvys Rodriguez-Abreu, David Aguiar, Marta Llanos, Ruth Alvarez, Natividad Martinez-Banaclocha, Jesús Alfaro, Cristina Quero, Ana Blasco, Luis de la Cruz Merino, Joaquín Herrero, Francisco R García-Arroyo & Mariano Provencio. (2019) Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. Leukemia & Lymphoma 60:6, pages 1576-1579.
Read now
Read now
Anat Gafter-Gvili & Aaron Polliack. (2016) Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leukemia & Lymphoma 57:3, pages 512-519.
Read now
Read now
Articles from other publishers (26)
Inna Y. Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika K. Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung & Michael Crump. (2023) Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada. British Journal of Haematology.
Crossref
Crossref
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Yuho Najima, Takeshi Kobayashi, Kyoko Haraguchi, Noriko Doki, Yoshiki Okuyama & Tatsu Shimoyama. (2023) Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study. Cancer Medicine.
Crossref
Crossref
Bouthaina Dabaja & Michael Spiotto. (2023) Radiation for hematologic malignancies: from cell killing to immune cell priming. Frontiers in Oncology 13.
Crossref
Crossref
Alira Fraga Olvera, Miguel Angel Saavedra-Salinas, Jesus Quetzalcoatl Beltrán Mendoza & Elizabeth Mendieta Flores. (2023) Prevalencia de hipogammaglobulinemia persistente en pacientes con enfermedad autoinmune que reciben rituximab en un centro de referencia nacional en México. Revista Alergia México 69:4, pages 171-182.
Crossref
Crossref
Montserrat Torres, Magdalena Corona, Sara Rodríguez-Mora, Guiomar Casado-Fernández, Alejandro Zurdo-Castronuño, Elena Mateos, Fernando Ramos-Martín, Clara Sánchez-Menéndez, María Aranzazú Murciano-Antón, Javier García-Pérez, José Alcamí, Mayte Pérez-Olmeda, Mayte Coiras, Javier López-Jiménez & Valentín García-Gutiérrez. (2022) Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster. Cancers 14:22, pages 5537.
Crossref
Crossref
E. E. Zvonkov, D. A. Koroleva, N. G. Gabeeva, A. E. Shchekina, M. A. Telyashov, O. A. Aleshina, B. V. Biderman, A. B. Sudarikov, T. N. Obukhova, I. V. Galtseva, V. N. Dvirnik, V. V. Troitskaya, G. M. Galstyan, M. A. Maschan & E. N. Parovichnikova. (2022) Combination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene. Russian journal of hematology and transfusiology 67:3, pages 441-452.
Crossref
Crossref
Muna Qayed, Joseph P. McGuirk, G. Doug Myers, Vinod Parameswaran, Edmund K. Waller, Peter Holman, Margarida Rodrigues, Lee F. Clough & Jennifer Willert. (2022) Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy 24:9, pages 869-878.
Crossref
Crossref
Manabu SuzukiDaisuke KoyamaShohei IkedaMasumi SukegawaMayumi TeshirogiKyohei Misawa & Saburo Tsunoda. (2022) Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. Journal of Clinical and Experimental Hematopathology 62:2, pages 91-98.
Crossref
Crossref
Charles L Bennett, Daniele Focosi, Mariana P Socal, Julia C Bian, Chadi Nabhan, William J Hrushesky, Andrew C Bennett, Martin W Schoen, Joseph R Berger & James O Armitage. (2021) Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. The Lancet Haematology 8:8, pages e593-e604.
Crossref
Crossref
Karthik Nath, Soi-Cheng Law, Muhammed B. Sabdia, Jay Gunawardana, Lilia M. de Long, David SesterMohamed Shanavas, Hennes Tsang, Joshua W. D. Tobin, Sarah-Jane HallidayAnnette HernandezDonna CrossRobert J. Bird, Sanjiv JainColm Keane, Dipti Talaulikar, Judith Trotman, Phillip Law & Maher K. Gandhi. (2021) Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances 5:12, pages 2644-2649.
Crossref
Crossref
Luca Pezzullo, Valentina Giudice, Bianca Serio, Raffaele Fontana, Roberto Guariglia, Maria Carmen Martorelli, Idalucia Ferrara, Laura Mettivier, Alessandro Bruno, Rosario Bianco, Emilia Vaccaro, Pasquale Pagliano, Nunzia Montuori, Amelia Filippelli & Carmine Selleri. (2021) Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Medicine 16:1, pages 672-682.
Crossref
Crossref
Penny Q. Fang, Jillian R. Gunther, Susan Y. Wu, Bouthaina S. Dabaja, Loretta J. Nastoupil, Sairah Ahmed, Sattva S. Neelapu & Chelsea C. Pinnix. (2021) Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in Oncology 11.
Crossref
Crossref
Yukiko Nakajima, Asuca Ogai, Karin Furukawa, Ryosuke Arai, Ryusuke Anan, Yasushi Nakano, Yuko Kurihara, Hideaki Shimizu, Takako Misaki & Nobuhiko Okabe. (2021) Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. Journal of Infection and Chemotherapy 27:2, pages 387-389.
Crossref
Crossref
M. Aapro, G.H. Lyman, C. Bokemeyer, B.L. Rapoport, N. Mathieson, N. Koptelova, P. Cornes, R. Anderson, P. Gascón & N.M. Kuderer. (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6:1, pages 100038.
Crossref
Crossref
Michael J. Buege, Anita Kumar, Brianne N. Dixon, Laura A. Tang, Terry Pak, Jennifer Orozco, Tim J. Peterson & Kathryn T. Maples. (2020) Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy 54:9, pages 879-898.
Crossref
Crossref
Joji Shimono, Koh Izumiyama, Shinichi Ito, Yutaka Tsutsmi, Takeshi Kondo, Yasutaka Kakinoki & Takanori Teshima. (2020) Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma. International Journal of Laboratory Hematology 42:4, pages 431-438.
Crossref
Crossref
Francesco D’Alò, Rosalia Malafronte, Francesca Piludu, Silvia Bellesi, Annarosa Cuccaro, Elena Maiolo, Anna Modoni, Lucia Leccisotti, Giuseppe Macis, Nadia Mores, Valerio De Stefano & Stefan Hohaus. (2020) Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance. British Journal of Haematology 189:4.
Crossref
Crossref
Joshua W.D. Tobin, Colm Keane, Jay Gunawardana & Maher K. Gandhi. (2020) Reply to M. Sorigue. Journal of Clinical Oncology 38:6, pages 648-649.
Crossref
Crossref
Tania Jain, Merav Bar, Ankit J. Kansagra, Elise A. Chong, Shahrukh K. Hashmi, Sattva S. Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A. Jacobson, Stephen M. Ansell, Farrukh T. Awan, Linda Burns, Veronika Bachanova, Catherine M. Bollard, Paul A. Carpenter, John F. DiPersio, Mehdi Hamadani, Helen E. Heslop, Joshua A. Hill, Krishna V. Komanduri, Craig A. Kovitz, Hillard M. Lazarus, Justin M. Serrette, Mohamad Mohty, David Miklos, Arnon Nagler, Steven Z. Pavletic, Bipin N. Savani, Stephen J. Schuster, Mohamed A. Kharfan-Dabaja, Miguel-Angel Perales & Yi Lin. (2019) Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation 25:12, pages 2305-2321.
Crossref
Crossref
Daniele Focosi, Marco Tuccori & Fabrizio Maggi. (2019) Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Reviews in Medical Virology 29:6.
Crossref
Crossref
Nicolás Martínez‐Calle, Sarah Hartley, Matthew Ahearne, Benjamin Kasenda, Amy Beech, Helen Knight, Constantine Balotis, Ben Kennedy, Simon Wagner, Martin J. S. Dyer, Dean Smith, Andrew K. McMillan, Fiona Miall, Mark Bishton & Christopher P. Fox. (2018) Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis. British Journal of Haematology 184:6, pages 957-968.
Crossref
Crossref
Blanka Kaplan & Vincent R. Bonagura. (2019) Secondary Hypogammaglobulinemia. Immunology and Allergy Clinics of North America 39:1, pages 31-47.
Crossref
Crossref
Monica Fung, Eric Jacobsen, Arnold Freedman, Daniel Prestes, Dimitrios Farmakiotis, Xiangmei Gu, Paul L Nguyen & Sophia Koo. (2019) Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clinical Infectious Diseases 68:2, pages 247-255.
Crossref
Crossref
Jonathan W. Friedberg. (2018) Progress in Advanced-Stage Follicular Lymphoma. Journal of Clinical Oncology 36:23, pages 2363-2365.
Crossref
Crossref
Johanna C. Kluin-Nelemans & Jeanette K. Doorduijn. (2018) What is the optimal initial management of the older MCL patient?. Best Practice & Research Clinical Haematology 31:1, pages 99-104.
Crossref
Crossref
. (2016) Bendamustine/rituximab. Reactions Weekly 1623:1, pages 43-43.
Crossref
Crossref